MX353827B - Formas de rifaximina y usos de la misma. - Google Patents

Formas de rifaximina y usos de la misma.

Info

Publication number
MX353827B
MX353827B MX2012009576A MX2012009576A MX353827B MX 353827 B MX353827 B MX 353827B MX 2012009576 A MX2012009576 A MX 2012009576A MX 2012009576 A MX2012009576 A MX 2012009576A MX 353827 B MX353827 B MX 353827B
Authority
MX
Mexico
Prior art keywords
rifaximin
forms
relates
present
therapeutic methods
Prior art date
Application number
MX2012009576A
Other languages
English (en)
Other versions
MX2012009576A (es
Inventor
S Gushurst Karen
Yang Donglai
Vlahova Petinka
S Stults Jeffrey
Original Assignee
Salix Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Salix Pharmaceuticals Ltd filed Critical Salix Pharmaceuticals Ltd
Publication of MX2012009576A publication Critical patent/MX2012009576A/es
Publication of MX353827B publication Critical patent/MX353827B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención se refiere a formas polimórficas de rifaximina, a su uso en preparaciones medicinales y a métodos terapéuticos que las utilizan.
MX2012009576A 2010-02-19 2011-02-16 Formas de rifaximina y usos de la misma. MX353827B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/708,836 US8486956B2 (en) 2008-02-25 2010-02-19 Forms of rifaximin and uses thereof
PCT/US2011/024981 WO2011103120A1 (en) 2010-02-19 2011-02-16 Forms of rifaximin and uses thereof

Publications (2)

Publication Number Publication Date
MX2012009576A MX2012009576A (es) 2012-12-05
MX353827B true MX353827B (es) 2018-01-31

Family

ID=44483273

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012009576A MX353827B (es) 2010-02-19 2011-02-16 Formas de rifaximina y usos de la misma.

Country Status (21)

Country Link
US (5) US8486956B2 (es)
EP (1) EP2536734B1 (es)
JP (2) JP2013520427A (es)
KR (1) KR20120140244A (es)
CN (2) CN102834398A (es)
AU (3) AU2011218258B2 (es)
BR (1) BR112012020863A2 (es)
CA (1) CA2790332A1 (es)
CR (1) CR20120449A (es)
EA (1) EA201270722A1 (es)
GE (2) GEP201706745B (es)
HK (1) HK1179608A1 (es)
IL (1) IL221299A (es)
MA (1) MA34058B1 (es)
MX (1) MX353827B (es)
MY (1) MY158992A (es)
NZ (1) NZ601670A (es)
SG (1) SG183188A1 (es)
TN (1) TN2012000414A1 (es)
WO (1) WO2011103120A1 (es)
ZA (1) ZA201206227B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3001996A (en) * 1957-02-08 1961-09-26 Hans S Mannheimer Sulfates and sulfonates of n-tertiary amino alkyl-carboxylic acid amides
PT1698630E (pt) 2005-03-03 2014-09-15 Alfa Wassermann Spa Novas formas polimorfas de rifaximina, processos para a sua produção e a sua utilização nas preparações medicinais
US8486956B2 (en) * 2008-02-25 2013-07-16 Salix Pharmaceuticals, Ltd Forms of rifaximin and uses thereof
EA021176B1 (ru) 2008-02-25 2015-04-30 Сэликс Фармасьютиклз, Лтд. Полиморфная форма рифаксимина и её применение
WO2010040020A1 (en) 2008-10-02 2010-04-08 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
US20110035232A1 (en) * 2008-10-02 2011-02-10 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
US7928115B2 (en) 2008-10-02 2011-04-19 Salix Pharmaceuticals, Ltd. Methods of treating travelers diarrhea and hepatic encephalopathy
WO2011061748A1 (en) * 2009-11-19 2011-05-26 Strides Arcolab Limited Rifaximin premix
US9018684B2 (en) 2009-11-23 2015-04-28 California Institute Of Technology Chemical sensing and/or measuring devices and methods
IT1398550B1 (it) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
CN103269587A (zh) * 2010-06-03 2013-08-28 萨利克斯药品有限公司 利福昔明的新形式及其用途
EP2582707A4 (en) * 2010-06-16 2014-01-08 Apotex Pharmachem Inc POLYMORPHIC FORMS OF RIFAXIMINE
MY165086A (en) * 2010-07-12 2018-02-28 Salix Pharmaceuticals Ltd Formulations of rifaximin and uses thereof
EP2616044A1 (en) * 2010-09-13 2013-07-24 Cilpa Limited Pharmaceutical composition
CN103827122B (zh) 2011-02-11 2016-08-31 萨利克斯药品有限公司 利福昔明的形式及其用途
AU2012251385A1 (en) * 2011-05-02 2013-11-21 Ranbaxy Laboratories Limited Rifaximin dimethylformamide solvate
ITMI20110890A1 (it) * 2011-05-19 2012-11-20 A M S A Anonima Materie Sint & Affini S P A Polimorfo di rifaximina e processo per la sua preparazione
CA2854380A1 (en) 2011-11-02 2013-05-10 Salix Pharmaceuticals, Ltd. Methods for treating irritable bowel syndrome (ibs) and infections
JP2013184902A (ja) * 2012-03-06 2013-09-19 Aska Pharmaceutical Co Ltd リファキシミン含有結晶
CA2876737A1 (en) 2012-06-13 2013-12-19 Apotex Pharmachem Inc. Polymorphic forms of rifaximin
ITBO20120368A1 (it) 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
EP2983647B1 (en) 2013-04-12 2020-09-09 Alfasigma S.p.A. Nsaid administration and related compositions, methods and systems
CN103509038B (zh) * 2013-09-30 2016-01-20 浙江思贤制药有限公司 一种新晶型利福昔明ζ及其制备方法
ES2621557T3 (es) 2014-03-31 2017-07-04 Euticals S.P.A. Mezcla polimórfica de rifaximina y su uso para la preparación de formulaciones sólidas
WO2015171493A1 (en) 2014-05-04 2015-11-12 Salix Pharmaceuticals, Inc. Ibs microbiota and uses thereof
JP6576953B2 (ja) 2014-05-12 2019-09-18 アルファシグマ ソシエタ ペル アチオニ リファキシミンの新規溶媒和物結晶形、生成物、組成物及びそれらの使用
WO2016204474A2 (ko) * 2015-06-18 2016-12-22 주식회사대성미생물연구소 리팍시민 결정체를 포함하는 동물 장염 치료용 수의학적 조성물
PT3518924T (pt) 2016-09-30 2022-10-27 Salix Pharmaceuticals Inc Formas de dispersão sólidas de rifaximina

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1154655B (it) 1980-05-22 1987-01-21 Alfa Farmaceutici Spa Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica
IT1199374B (it) 1984-05-15 1988-12-30 Alfa Farmaceutici Spa Processo per la preparazione di pirido-imidazo-rifamicine
US20020048610A1 (en) 2000-01-07 2002-04-25 Cima Michael J. High-throughput formation, identification, and analysis of diverse solid-forms
ITMI20032144A1 (it) * 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
US7923553B2 (en) 2003-11-07 2011-04-12 Alfa Wassermann, S.P.A. Processes for the production of polymorphic forms of rifaximin
US20080262024A1 (en) 2003-11-07 2008-10-23 Giuseppe Claudio Viscomi Rifaximin compositions and method of use
US7906542B2 (en) 2004-11-04 2011-03-15 Alfa Wassermann, S.P.A. Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin
US7902206B2 (en) 2003-11-07 2011-03-08 Alfa Wassermann, S.P.A. Polymorphic forms α, β and γ of rifaximin
DE102004004433A1 (de) 2004-01-28 2005-08-18 Trützschler GmbH & Co KG Vorrichtung an einer Spinnereimaschine, insbesondere Karde, Reiniger o. dgl., zum Aufziehen einer Garnitur auf eine Walze
ATE427311T1 (de) * 2004-07-22 2009-04-15 Cumbre Pharmaceuticals Inc (r/s) rifamycin-derivate, ihre herstellung und pharmazeutische zusammensetzungen
US8003118B2 (en) 2005-03-02 2011-08-23 Kodsi Robert E Use of rifaximin for the prevention of aspiration pneumonia and/or sepsis
PT1698630E (pt) 2005-03-03 2014-09-15 Alfa Wassermann Spa Novas formas polimorfas de rifaximina, processos para a sua produção e a sua utilização nas preparações medicinais
ITBO20050123A1 (it) 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
NZ575550A (en) 2006-09-22 2011-12-22 Cipla Ltd Rifaximin
WO2008085484A2 (en) 2006-12-28 2008-07-17 Jacobus Pharmaceutical Company, Inc. Treatment of inflammatory bowel disease with enteric coated formulations comprising 5-aminosalicylic acid or 4-aminosalicylic acid
ITMI20071241A1 (it) 2007-06-20 2008-12-21 Solmag S P A Processo per la preparazione di rifaximina amorfa e rifaximina amorfa cosi' ottenuta
AU2008273699A1 (en) 2007-07-06 2009-01-15 Lupin Limited Pharmaceutical compositions of rifaximin
MY144578A (en) * 2007-07-27 2011-10-14 Alfa Wassermann Spa New polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations
US7709634B2 (en) 2007-09-20 2010-05-04 Apotex Pharmachem Inc. Amorphous form of rifaximin and processes for its preparation
JP2011500552A (ja) 2007-10-10 2011-01-06 ルピン・リミテッド 胃腸障害を処置するための医薬用組み合わせおよび組成物
EA021176B1 (ru) 2008-02-25 2015-04-30 Сэликс Фармасьютиклз, Лтд. Полиморфная форма рифаксимина и её применение
US8486956B2 (en) 2008-02-25 2013-07-16 Salix Pharmaceuticals, Ltd Forms of rifaximin and uses thereof
SI2294012T1 (sl) 2008-05-07 2014-11-28 Salix Pharmaceuticals, Ltd. Dajanje ÄŤistila za ÄŤrevo in antibiotika za zdravljenje ÄŤrevesne bolezni
AU2009292615B2 (en) 2008-09-17 2015-12-03 Mylan Inc. Granulates, process for preparing them and pharmaceutical products containing them
KR20110107806A (ko) 2008-12-10 2011-10-04 시플라 리미티드 리팍시민 복합체
PE20121185A1 (es) 2009-10-27 2012-09-15 Lupin Ltd Dispersion solida de rifaximina
US8952159B2 (en) 2009-12-28 2015-02-10 Silvio Massimo Lavagna Method for the production of amorphous rifaximin
CN103269587A (zh) * 2010-06-03 2013-08-28 萨利克斯药品有限公司 利福昔明的新形式及其用途
EP2582707A4 (en) * 2010-06-16 2014-01-08 Apotex Pharmachem Inc POLYMORPHIC FORMS OF RIFAXIMINE
CN103827122B (zh) * 2011-02-11 2016-08-31 萨利克斯药品有限公司 利福昔明的形式及其用途

Also Published As

Publication number Publication date
CR20120449A (es) 2012-11-29
WO2011103120A1 (en) 2011-08-25
AU2014246594B2 (en) 2016-09-15
EP2536734A4 (en) 2013-06-26
CA2790332A1 (en) 2011-08-25
US9034892B2 (en) 2015-05-19
AU2014246594A1 (en) 2014-10-30
SG183188A1 (en) 2012-09-27
HK1179608A1 (zh) 2013-10-04
AU2011218258B2 (en) 2015-11-05
JP2016094416A (ja) 2016-05-26
AU2016269529B2 (en) 2018-06-07
US20120316334A1 (en) 2012-12-13
US20100174064A1 (en) 2010-07-08
AU2011218258A1 (en) 2012-08-30
IL221299A (en) 2017-11-30
KR20120140244A (ko) 2012-12-28
US8569326B2 (en) 2013-10-29
CN102834398A (zh) 2012-12-19
AU2016269529A1 (en) 2017-01-05
BR112012020863A2 (pt) 2016-06-21
US8486956B2 (en) 2013-07-16
NZ601670A (en) 2014-11-28
US20160200738A1 (en) 2016-07-14
US9546183B2 (en) 2017-01-17
ZA201206227B (en) 2018-12-19
TN2012000414A1 (en) 2014-01-30
EA201270722A1 (ru) 2013-03-29
MX2012009576A (es) 2012-12-05
JP2013520427A (ja) 2013-06-06
GEP20156230B (en) 2015-01-26
MA34058B1 (fr) 2013-03-05
US20140179916A1 (en) 2014-06-26
MY158992A (en) 2016-11-30
IL221299A0 (en) 2012-10-31
US20140141081A1 (en) 2014-05-22
EP2536734B1 (en) 2016-08-31
GEP201706745B (en) 2017-10-10
US9273066B2 (en) 2016-03-01
EP2536734A1 (en) 2012-12-26
CN105254647A (zh) 2016-01-20

Similar Documents

Publication Publication Date Title
TN2012000414A1 (en) Forms of rifaximin and uses thereof
TN2012000611A1 (en) Formulations of rifaximin and uses thereof
HK1252481A1 (zh) 疏水性治療劑的製劑、其製備方法及應用
MY158257A (en) Forms of rifaximin and uses thereof
PH12015500274B1 (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
MX2013008390A (es) Preparacion de estructuras de metal-triazolato.
IN2012DN01920A (es)
NZ629697A (en) Human anti-cd27 antibodies, methods and uses
SG10201808102WA (en) Bicyclic heterocycle compounds and their uses in therapy
WO2012030993A3 (en) Skin compositions and methods of use thereof
HUE041553T2 (hu) Lizoszomális tárolási betegségek (LSD) kezelése és génterápia
MX349004B (es) Nuevos compuestos.
GB201106750D0 (en) Novel compounds
MX2016008448A (es) Conjugados de var2csa-farmaco.
MX366899B (es) Nuevos compuestos.
MX347734B (es) Anticuerpos anti-s100a4 y usos aplicaciones terapéuticas.
UA110103C2 (uk) Модифікований туберкульозний антиген
PH12014501991B1 (en) Phenicol antibacterials
MX350448B (es) Formas de rifaximina y usos de las mismas.
IN2014DN06104A (es)
MX2014009750A (es) Composiciones antifungicas para el tratamiento de piel y uñas.
GB201213484D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods of using the same
MX2013003859A (es) Polimorfos de picropodofilina b o c para su uso en la terapia del cancer.
MX2023003000A (es) Formulaciones de liberacion modificada de viloxacina.
MX2013008559A (es) Derivados de leptina.

Legal Events

Date Code Title Description
FG Grant or registration